Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0V9VG
|
|||
Former ID |
DIB014941
|
|||
Drug Name |
Rimegepant
|
|||
Synonyms |
BMS-927711; 1289023-67-1; UNII-997WVV895X; BMS 927711; CHEMBL2178422; 997WVV895X; (5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate; Rimegepant [USAN:INN]; Rimegepant (USAN/INN); SCHEMBL1670580; DTXSID70156003; C28H28F2N6O3; EX-A1922; 3504AH; ZINC68267814; BDBM50400098; AKOS030526382; DB12457; CS-1027; NCGC00378677-01; HY-15498; KB-145921; W-5991
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Migraine [ICD-11: 8A80; ICD-10: G43, G43.9; ICD-9: 346] | Approved | [1] | |
Company |
Labrys Biologics
|
|||
Structure |
Download2D MOL |
|||
Formula |
C28H28F2N6O3
|
|||
Canonical SMILES |
C1CC(C2=C(C=CC=N2)C(C1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6
|
|||
InChI |
1S/C28H28F2N6O3/c29-20-6-1-4-17(23(20)30)18-8-9-22(25-19(24(18)31)5-2-12-32-25)39-28(38)35-14-10-16(11-15-35)36-21-7-3-13-33-26(21)34-27(36)37/h1-7,12-13,16,18,22,24H,8-11,14-15,31H2,(H,33,34,37)/t18-,22+,24-/m0/s1
|
|||
InChIKey |
KRNAOFGYEFKHPB-ANJVHQHFSA-N
|
|||
CAS Number |
CAS 1289023-67-1
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Calcitonin gene-related peptide receptor (CGRPR) | Target Info | Antagonist | [1] |
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
Vascular smooth muscle contraction | ||||
Reactome | G alpha (s) signalling events | |||
Calcitonin-like ligand receptors | ||||
WikiPathways | GPCRs, Class B Secretin-like | |||
Endothelin Pathways | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.